Cargando…

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma

Lisocabtagene maraleucel (liso‐cel) is an autologous, CD19‐directed, chimeric antigen receptor T‐cell product for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma (LBCL) after 2 or more lines of systemic therapy. In vivo cellular expansion after single‐dose administr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogasawara, Ken, Lymp, James, Mack, Timothy, Dell’Aringa, Justine, Huang, Chang‐pin, Smith, Jeff, Peiser, Leanne, Kostic, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311712/ https://www.ncbi.nlm.nih.gov/pubmed/35156195 http://dx.doi.org/10.1002/cpt.2561

Ejemplares similares

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
por: Abramson, Jeremy S., et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
por: Olson, N. Eric, et al.
Publicado: (2023)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Lip reading role in the hearing aid fitting process
por: Bannwart Dell'Aringa, Ana Helena, et al.
Publicado: (2015)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

Notch signaling represents an important checkpoint between follicular T-helper and canonical T-helper 2 cell fate
por: Dell'Aringa, Mark, et al.
Publicado: (2018)

The importance of the auditory evoked potential in acoustic neuromas
por: Dell’Aringa, Ana Helena Bannwart, et al.
Publicado: (2015)

Audiological findings in pacients treated with radiotherapy for head and neck tumors
por: Dell'Aringa, Ana Helena Bannwart, et al.
Publicado: (2015)

Rio’s Mountainous Region (“Região Serrana”) 2011 Landslides: Impact on Public Mental Health System
por: Dell'Aringa, Marcelo, et al.
Publicado: (2018)

Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors
por: Dell'Aringa, Ana Helena B, et al.
Publicado: (2009)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
por: Ogasawara, Ken, et al.
Publicado: (2019)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Cytokine expression by invariant natural killer T cells is tightly regulated throughout development and settings of type-2 inflammation
por: O'Brien, T F, et al.
Publicado: (2016)

Spontaneus tonsillar hemorrhage
por: Milhomem Rocha, Savya Cybelle, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Usher’s syndrome
por: Norte, Maria Carolina Braga, et al.
Publicado: (2015)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Treatment approaches in relapsed or refractory peripheral T-cell lymphomas
por: Foster, Cheryl, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fkoh5q7bt49araem84dn12ahqs